Re:Cognition Health

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease13 trials
• Bipolar disorder1 trial
• Depression1 trial
• Lewy body dementia1 trial

Phase

• Phase 310 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Completed5 trials
• Recruiting4 trials
• Active, not recruiting3 trials
• Terminated3 trials

Lead sponsor

• Eli Lilly and Company6 trials
• Alzheon Inc.2 trials
• Cassava Sciences, Inc.2 trials
• Hoffmann-La Roche2 trials
• Asceneuron S.A.1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

  Contact: Raymond Turner (principal investigator)

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

  Contact: Scott Williams (principal investigator)

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Eli Lilly and Company· Source

  Contact: Scott Williams (principal investigator)

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Bipolar disorder1 recruiting
• Depression1 recruiting
• Lewy body dementia1 recruiting

Closed trials

• Terminated

  Study of ASN51 in Adults With Early Alzheimer's Disease

  NCT06677203· Phase 2· Asceneuron S.A.· Source

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Phase 3· Alzheon Inc.· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

  NCT05364307· Global Alzheimer's Platform Foundation· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Completed

  SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

  NCT04381468· Phase 1/2· Vaccinex Inc.· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Alzheon Inc.· Source